Literature DB >> 26223919

Neuroprotective effect of escitalopram oxalate in rats with chronic hypoperfusion.

Li Ma1, Zu-Neng Lu2, Pei Hu3, Chang-Jiang Yao3.   

Abstract

The neuroprotective effects of escitalopram oxalate in rats with chronic hypoperfusion and the possible mechanism were explored. Chronic hypoperfusion (2-VO) model was prepared and given escitalopram oxalate (experimental group) or PBS (control group) after 6 weeks. Eight weeks after the operation, Morris water maze test was carried out to evaluate the learning and memory ability of the rats. The cell proliferation, three-dimensional vascular distribution, cell morphological changes in ischemic area and the plasma vascular endothelial growth factor (VEGF) were detected to explore the possible mechanisms. (1) Morris water maze test showed that the escape latency in the experimental group was significantly shorter than in the control group, while the first quadrant swimming time in the experimental group was significantly longer than the control group (both P<0.01). (2) Cerebrovascular confocal detection results showed that the inside diameter of capillaries was significantly less in the experimental group than in the control group; the vascular density was significantly increased in the experimental group and the total area of capillaries was also significantly increased in the experimental group as compared with the control group. (3) There was statistically significant difference in BrdU-positive cells in the ischemic brain tissue between the experimental group and the control group (P=0.003<0.01). (4) VEGF concentrations in the plasma and the ischemic area were higher in the experimental group than in the control group (P<0.05). It was concluded that escitalopram oxalate could significantly improve the learning and memory ability of the rats with chronic cerebral ischemia probably by the VEGF-mediated angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26223919     DOI: 10.1007/s11596-015-1462-x

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  10 in total

Review 1.  Targets for vascular protection after acute ischemic stroke.

Authors:  Susan C Fagan; David C Hess; Elizabeth J Hohnadel; David M Pollock; Adviye Ergul
Journal:  Stroke       Date:  2004-07-29       Impact factor: 7.914

2.  Antidepressants in the treatment of stroke.

Authors:  Megan M Burns; David A Greenberg
Journal:  Expert Rev Neurother       Date:  2010-08       Impact factor: 4.618

3.  Depletion in serotonin decreases neurogenesis in the dentate gyrus and the subventricular zone of adult rats.

Authors:  J M Brezun; A Daszuta
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

4.  Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats.

Authors:  J Chen; P R Sanberg; Y Li; L Wang; M Lu; A E Willing; J Sanchez-Ramos; M Chopp
Journal:  Stroke       Date:  2001-11       Impact factor: 7.914

Review 5.  Vascular endothelial growth factor (VEGF) and its role in the central nervous system: a new element in the neurotrophic hypothesis of antidepressant drug action.

Authors:  Marta Maria Nowacka; Ewa Obuchowicz
Journal:  Neuropeptides       Date:  2011-06-29       Impact factor: 3.286

6.  Bone marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse.

Authors:  Zheng Gang Zhang; Li Zhang; Quan Jiang; Michael Chopp
Journal:  Circ Res       Date:  2002-02-22       Impact factor: 17.367

Review 7.  [VEGF as an angiogenic, neurotrophic, and neuroprotective factor].

Authors:  Magdalena Namiecińska; Katarzyna Marciniak; Jerzy Z Nowak
Journal:  Postepy Hig Med Dosw (Online)       Date:  2005       Impact factor: 0.270

8.  Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke.

Authors:  Anna Kozak; Adviye Ergul; Azza B El-Remessy; Maribeth H Johnson; Livia S Machado; Hazem F Elewa; Mohammed Abdelsaid; Daniel C Wiley; Susan C Fagan
Journal:  Stroke       Date:  2009-03-05       Impact factor: 7.914

9.  VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants.

Authors:  Jennifer L Warner-Schmidt; Ronald S Duman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-05       Impact factor: 11.205

10.  Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization.

Authors:  Joshua Greene; Mounira Banasr; Boyoung Lee; Jennifer Warner-Schmidt; Ronald S Duman
Journal:  Neuropsychopharmacology       Date:  2009-06-24       Impact factor: 7.853

  10 in total
  1 in total

Review 1.  Potential Role of Selective Serotonin Reuptake Inhibitors in Improving Functional Outcome after Stroke.

Authors:  Janne Kaergaard Mortensen; Grethe Andersen
Journal:  CNS Drugs       Date:  2018-10       Impact factor: 5.749

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.